Gossamer Bio, Inc. (NASDAQ: GOSS) (the "Company" or "Gossamer"), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial ...
NEW YORK, June 25, 2026 /PRNewswire/ -- Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today ...
SAN DIEGO, June 03, 2026--(BUSINESS WIRE)--Gossamer Bio, Inc. (NASDAQ: GOSS) (the "Company" or "Gossamer"), a biopharmaceutical company focused on the development and commercialization of seralutinib ...
BridgeBio Pharma plans to offer $500 million in convertible senior notes, aiming to strengthen its financial position and reduce interest expenses. BridgeBio Pharma, Inc. announced plans to offer $500 ...
Refinancing term debt facility lowers interest expense, eliminates near-term amortization payments, and significantly extends debt maturity Offering priced at 1.75% interest rate and 45% conversion ...
Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new investment opportunities through TipRanks' ...
Nuvation Bio's shares retreated after the oncology company said it planed sell $200 million in convertible bonds. In premarket trading, the shares were down 12% at $5.70. As of the last close, the ...
Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis. Discover high-conviction stock picks and new investing ...
Gossamer Bio, Inc. (NASDAQ: GOSS) (the “Company” or “Gossamer”), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results